Tampa, Florida, United States – January 7, 2025 – CTT Pharmaceutical Holdings Inc.(OTC:CTTH) and Johns Hopkins University have successfully submitted our
proposal for a NIH Grant that will utilize CTT’s patented technology as a smoking cessation product. This grant will allow for clinical trials to be conducted and up to $15 million given to cover these trials. The NIH will begin the review process of this proposal in April 2025 and will notify Johns Hopkins University and CTT Pharma of the results. The CEO of CTT Pharma, Ryan Khouri stated, This brings us one step closer to helping smokers quit, as 480,000 Americans die every year or 1300 per day from the effects of smoking. The last oral nicotine product that was FDA Approved for smoking cessation was Nicorette gum in 1984. While Nicorette gum has helped many people quit smoking, I believe consumers need more options to quit. CTT’s fast acting dissolvable nicotine strips would use substantially less nicotine per dose compared to Nicorette Gum and also dissolve in seconds compared to the gum staying in the mouth for 30 minutes. I also want to price our patented technology at or below the price of Nicorette gum, as pricing of our product should not be a deterrent for a consumer looking to quit smoking. Upon approval from the NIH I’m confident in our teams ability to execute our technology and do not anticipate any problems arising. Johns Hopkins University will be in charge of the clinical trials from start to finish. This past October I attended and briefly spoke at a FDA/NIH hearing about advancing smoking cessation technology. I personally met with many individuals who work for both the FDA and NIH and had productive conversations Furthermore, I have been asked to appear on Fox Business and Bloomberg for interviews in regards to this grant and have interest in doing both shows. I would prefer to do these interviews once our proposal has been approved but l’m considering doing them beforehand. I firmly believe CTT Pharma’s dissolvable nicotine strips are a viable solution to a worldwide problem and should be used as a tool to get people to stop smoking. The World Health Organization states, “The tobacco epidemic is one of the biggest public health threats the world has ever faced, killing over 8 million people a year around the world. More than 7 million of those deaths are results of direct tobacco use while 1.3 million are the result of non- smokers being exposed to second-hand smoke.” The CDC says, “Cigarette smoking is the leading cause of preventable death in the United States. Cigarette smoking causes more than 480,000 deaths each year in the United States. This is nearly one in five deaths.” CTT will continue to update shareholders as more news becomes available.

CTT Pharma – 813-606-0060

Tampa, FL. August 21, 2024 – Newswire – CTT Pharmaceuticals Holdings, Inc. (OTC: CTTH), is pleased to announce that the registered PCAOB Accounting Firm of DiPiazza, LaRocca, Heeter & Co., led by audit partne Matthew Stewart have successfully completed the 2 year audit of CTT Pharma. This comprehensive audit
included the review of CiT’s bank statements, patents, contracts and share allocation over the past 2 years and has received the necessary approvals to allow CIT Pharma to be in compliance with PCAOB Regulations. The
PCAOB Audit Letter and Audited Financials for 2022 and 2023 have been successful uploaded to the Olf Markets Website for anyone to view. This important milestone will allow CTT to uplist at any point now and should also give existing shareholders, future shareholders, investment firms and potential partners including the U.S. Government and other partnerships that may arise the necessary confidence in our management tear that on a day to day basis CTT is functioning at the highest level of integrity.

The Public Company Accounting Oversight Board protects investors and other stakeholders of public companies by ensuring that the auditor of a company’s financial statements has followed a set of strict guidelines to minimize audit risk. The PCAOB is a non-profit organization that regulates auditors of publicly traded companies and oversees the audits of public companies, brokers, and dealers registered with the U.S. Securities and Exchange Commission (SEC), Ran Khouri. CFO of CIT Pharma. stated. “This PCAOB Audit was very extensive and should ensure a level of confidence amongst existing and future shareholders, while allowing C I the ability to uplist to the OlCQB. Furthermore, I will continue to work hard to gain traction with the U.S. Government for the necessary grants and loans to help launch our Nicotine Strips as the tobacco industry is long overdue for CT’s technology, which would be a low dose, fast dissolving nicotine strip. The market currently offers cigarettes, vaping and oral deliverables that stay in the mouth for extended periods of time and have significantly higher amounts of nicotine in these products. There’s 480,000 Americans that will die this year from the effects of smoking or the equivalent of 1300 Americans losing their life daily. I look forward to continue the fight to not only help this industry but also make an impact on many other industries using our patented technology.

About CT Pharmaceuticals Holdings, Inc.
CIT has granted and pending patents for our technology in the United States, Europe, Canada and several other countries around the world that allow for many drugs to be put on dissolvable strips and other oral products including but not limited to Pharmaceuticals, Nicotine, Liraglutide, Vitamins, and Caffeine. This patented technology allows for better bioavailability/absorption, quick onset, and the ability to make low dose dissolvable
strips.

Company Info: Phone: 813-606-0060 Twitter/X: @CTT Pharmi